Biopharmaceutical company.
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
TIBER CREEK GROUP
750 9th Street NW, Suite 501, Washington, DC, 20001, US
BRYANT HALL JONATHON JONES COREY MALMGREN